Chemistry:AC-262,536
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C18H18N2O |
| Molar mass | 278.355 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a Ki of 5 nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the levator ani muscle weight increase of testosterone, but only around 27% of its maximal effect on prostate gland weight.[1][2][3] It is an aniline SARM related to ACP-105 and vosilasarm (RAD140).[4]
References
- ↑ "Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator". J Steroid Biochem Mol Biol 109 (1–2): 129–37. March 2008. doi:10.1016/j.jsbmb.2007.11.001. PMID 18164613.
- ↑ "Equine metabolism of the selective androgen receptor modulator AC-262536 in vitro and in urine, plasma and hair following oral administration". Drug Testing and Analysis 13 (2): 369–385. February 2021. doi:10.1002/dta.2932. PMID 32959959. https://biblio.ugent.be/publication/8694577.
- ↑ "Simultaneous detection of different chemical classes of selective androgen receptor modulators in urine by liquid chromatography-mass spectrometry-based techniques". Journal of Pharmaceutical and Biomedical Analysis 195: 113849. February 2021. doi:10.1016/j.jpba.2020.113849. PMID 33383501.
- ↑ "Deciphering the selective androgen receptor modulators paradigm". Expert Opinion on Drug Discovery 8 (2): 191–218. February 2013. doi:10.1517/17460441.2013.741582. PMID 23231475.
 |  |
